Reuters: Regulatory News: Teva Pharm gets Europe backing for Lonquex drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Teva Pharm gets Europe backing for Lonquex drug Jun 3rd 2013, 08:43 JERUSALEM, June 3 | Mon Jun 3, 2013 4:43am EDT JERUSALEM, June 3 (Reuters) - Israel's Teva Pharmaceutical Industries has moved closer to selling its Lonquex drug for the treatment of neutropenia, a complication of chemotherapy, after a panel recommended its sale in the European Union. The Committee for Medicinal Products for Human Use (CHMP) recommended that a marketing authorisation be issued in the EU for Lonquex for the reduction of neutropenia, Teva said on Monday. "The CHMP positive opinion opens the way to a final approval decision from the European Commission expected within the next few months," said Teva, the world's largest generics drugmaker. Teva, which is stepping up efforts to sell branded drugs, said it was seeking to provide new treatment options for cancer patients, a key area for the company. Neutropenia is a common and potentially hazardous complication of chemotherapy treatment characterised by a decreased level of white blood cells, which can expose the patient to serious bacterial infections, Teva said.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions